Flow cytometry, which uses fluorescent tags to sort cells one by one according to their properties, is a workhorse of cell biology. But as a sorting technique, flow cytometry tops out at about half a dozen different tags. Read More
EpiTherapeutics ApS is a little company with big plans. Last December, the Copenhagen, Denmark-based firm inked its first drug discovery agreement with Abbott, of Abbott Park, Ill., to develop cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets. Read More
Biovista Inc., of Charlottesville, Va., said its European Union affiliate has been awarded a $500,000 grant for R&D in personalized medicine as part of the "p-medicine" project, a four-year effort under the European Community's 7th Framework Programme. Biovista said it will use its Clinical Outcomes Search Space platform multidimensional profiling capabilities to identify treatments that reflect patients' individual pathophysiological characteristics. Read More
Cadence Pharmaceuticals Inc., of San Diego, reported the company's first-ever revenue, with sales of recently launched Ofirmev (acetaminophen) injection, an intravenous formulation of acetaminophen, driving net revenue of $350,000. Read More
Shares in Wilex AG rose almost 20 percent earlier this week on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million. Read More
Oncothyreon Inc., of Seattle, said the underwriters of its recently completed $40 million public stock offering fully exercised their overallotment option, boosting the gross proceeds to $46 million. Net proceeds of $43 million will support Oncothyreon's Phase I and Phase II cancer pipeline. Read More
Pearl Therapeutics Inc., of Redwood City, Calif., presented results of three studies evaluating its porous particle-based metered dose inhaler at the Respiratory Drug Delivery Europe meeting in Berlin. The data showed that the device efficiently delivers respiratory medicines and that the porous particles are practically insoluble in hydrofluoroalkane propellant, associating with micronized drug crystals so that unwanted interactions are minimized. The platform will be developed with long-acting muscarinic antagonists, long acting beta-2 adrenergic receptor agonists and inhaled corticosteroids. Read More
